


CLAIMS

1. A compound of formula (I):



5

(I)

wherein

- R^1 is selected from hydrogen, C_{1-6} alkyl optionally substituted by up to three groups independently selected from C_{1-6} alkoxy, halogen and hydroxy, C_{2-6} alkenyl, C_{3-7} cycloalkyl optionally substituted by one or more C_{1-6} alkyl groups, phenyl optionally substituted by up to three groups independently selected from R^5 and R^6 , and heteroaryl optionally substituted by up to three groups independently selected from R^5 and R^6 ,

- R^2 is selected from hydrogen, C_{1-6} alkyl and $-(\text{CH}_2)_q\text{-C}_{3-7}$ cycloalkyl optionally substituted by one or more C_{1-6} alkyl groups,

or $(\text{CH}_2)_m\text{R}^1$ and R^2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C_{1-6} alkyl groups;

R^3 is chloro or methyl;

- R^4 is the group $-\text{NH-CO-R}^7$ or $-\text{CO-NH-(CH}_2)_q\text{-R}^8$;

R^5 is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-(\text{CH}_2)_q\text{-C}_{3-7}$ cycloalkyl optionally substituted by one or more C_{1-6} alkyl groups, $-\text{CONR}^9\text{R}^{10}$, $-\text{NHCOR}^{10}$, $-\text{SO}_2\text{NHR}^9$, $-(\text{CH}_2)_s\text{NHSO}_2\text{R}^{10}$, halogen, CN, OH, $-(\text{CH}_2)_s\text{NR}^{11}\text{R}^{12}$, and trifluoromethyl;

- R^6 is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl and $-(\text{CH}_2)_s\text{NR}^{11}\text{R}^{12}$;

R^7 is selected from hydrogen, C_{1-6} alkyl, $-(\text{CH}_2)_q\text{-C}_{3-7}$ cycloalkyl optionally substituted by one or more C_{1-6} alkyl groups, trifluoromethyl, $-(\text{CH}_2)_r$ heteroaryl optionally substituted by R^{13} and/or R^{14} , and $-(\text{CH}_2)_r$ phenyl optionally substituted by R^{13} and/or R^{14} ;

- R^8 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl optionally substituted by one or more C_{1-6} alkyl groups, CONHR^9 , phenyl optionally substituted by R^{13} and/or R^{14} , and heteroaryl optionally substituted by R^{13} and/or R^{14} ;

- R^9 and R^{10} are each independently selected from hydrogen and C_{1-6} alkyl,
 or R^9 and R^{10} , together with the nitrogen atom to which they are bound, form a
 five- to six-membered heterocyclic ring optionally containing one additional heteroatom
 selected from oxygen, sulfur and N- R^{15} , wherein the ring may be substituted by up to two
 5 C_{1-6} alkyl groups;
 R^{11} is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl optionally
 substituted by one or more C_{1-6} alkyl groups,
 R^{12} is selected from hydrogen and C_{1-6} alkyl,
 or R^{11} and R^{12} , together with the nitrogen atom to which they are bound, form a
 10 five or six-membered heterocyclic ring optionally containing one additional heteroatom
 selected from oxygen, sulfur and N- R^{15} ;
 R^{13} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_q-C_{3-7}$ cycloalkyl optionally
 substituted by one or more C_{1-6} alkyl groups, $-CONR^9R^{10}$, $-NHCOR^{10}$, halogen, CN, $-(CH_2)_sNR^{11}R^{12}$, trifluoromethyl, phenyl optionally substituted by one or more R^{14}
 15 groups and heteroaryl optionally substituted by one or more R^{14} groups;
 R^{14} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl and $-NR^{11}R^{12}$;
 R^{15} is selected from hydrogen and methyl;
 X and Y are each independently selected from hydrogen, methyl and halogen;
 20 m is selected from 0, 1, 2, 3 and 4, wherein each carbon atom of the resulting
 carbon chain may be optionally substituted with up to two groups selected independently
 from C_{1-6} alkyl and halogen;
 q is selected from 0, 1 and 2;
 r is selected from 0 and 1; and
 25 s is selected from 0, 1, 2 and 3;
 or a pharmaceutically acceptable derivative thereof.
2. A compound according to claim 1 wherein R^1 is selected from C_{1-6} alkyl optionally
 substituted by up to three groups independently selected from C_{1-6} alkoxy, halogen and
 30 hydroxy, and phenyl optionally substituted by up to three groups independently selected
 from R^5 and R^6 .
3. A compound according to claim 1 or claim 2 wherein R^2 is hydrogen.
- 35 4. A compound according to any one of the preceding claims wherein R^3 is methyl.
5. A compound according to any one of the preceding claims wherein X is fluorine.
6. A compound according to any one of the preceding claims wherein R^4 is $-CO-NH-$
 40 $(CH_2)_q-R^8$.
7. A compound according to any one of the preceding claims wherein R^8 is C_{3-6}
 cycloalkyl optionally substituted by one or more C_{1-6} alkyl groups.

8. A compound according to claim 1 or a pharmaceutically acceptable derivative thereof substantially as hereinbefore defined with reference to any one of Examples 1 to 20.

5

9 A compound according to any one of the preceding claims selected from:

6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-(2,2-dimethylpropyl)-3-pyridinecarboxamide 1-oxide;

10 6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-[(1*R*)-1,2,2-trimethylpropyl]-3-pyridinecarboxamide 1-oxide;

6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-(1,1-dimethylpropyl)-3-pyridinecarboxamide 1-oxide;

6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-(1-ethylpropyl)-3-pyridinecarboxamide 1-oxide;

15 6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-[(1*S*)-1,2,2-trimethylpropyl]-3-pyridinecarboxamide 1-oxide;

6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-[(1*R*)-1,2-dimethylpropyl]-3-pyridinecarboxamide 1-oxide;

20 6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-[(1*S*)-1,2-dimethylpropyl]-3-pyridinecarboxamide 1-oxide; and

6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-*N*-[(3,4-dimethylphenyl)methyl]-3-pyridinecarboxamide 1-oxide;
and pharmaceutically acceptable derivatives thereof.


25 10. A pharmaceutical composition comprising at least one compound as claimed in any one of claims 1 to 9 or a pharmaceutically acceptable derivative thereof in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.

30 11. A method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound as claimed in any one of claims 1 to 9 or a pharmaceutically acceptable derivative thereof.

35 12. A compound as claimed in any one of claims 1 to 9 or a pharmaceutically acceptable derivative thereof for use in therapy.

40 13. Use of a compound as claimed in any one of claims 1 to 9 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for use in the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

14. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 9 or a pharmaceutically acceptable derivative thereof which comprises reacting compound of formula (II)



5

(II)

in which R¹, R², R³, R⁴, X, Y and m are as defined in claim 1, with an oxidising agent.